Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
Amyloid Fibrils03:03

Amyloid Fibrils

9.7K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

608
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
608
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

650
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
650
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Excitatory and Inhibitory Effects of Neurotransmitters01:29

Excitatory and Inhibitory Effects of Neurotransmitters

10.3K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

To treat or not to treat: The clue lies in multimodal imaging.

Indian journal of ophthalmology·2026
Same author

Blinded by precision-laser induced macular injury.

Eye (London, England)·2026
Same author

Feathery cataract.

Eye (London, England)·2026
Same author

Penetration with inflation: post traumatic air in AC.

Eye (London, England)·2026
Same author

Propagation of α-synuclein pathology: models, mechanisms and future goals.

Molecular neurodegeneration advances·2026
Same author

A genome-wide association study of young onset Parkinson's disease in European ancestry.

medRxiv : the preprint server for health sciences·2026
Same journal

Exercise as a regulator of glymphatic function.

Trends in neurosciences·2026
Same journal

The neural basis of laughter.

Trends in neurosciences·2026
Same journal

Enteric neuroimmune interactions in health and disease.

Trends in neurosciences·2026
Same journal

Atomic insights into the physiological and functional diversity of NMDA receptors.

Trends in neurosciences·2026
Same journal

Cognitive functions of the GPe.

Trends in neurosciences·2026
Same journal

Re-examining the structure-function relationship in tactile corpuscles.

Trends in neurosciences·2026
See all related articles

Related Experiment Video

Updated: Aug 16, 2025

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.7K

α-Synuclein in synaptic function and dysfunction.

Manu Sharma1, Jacqueline Burré1

  • 1Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.

Trends in Neurosciences
|December 25, 2022
PubMed
Summary
This summary is machine-generated.

Alpha-synuclein, a neuronal protein, plays a role in neurotransmitter release. Its aggregation in synucleinopathies like Parkinson's disease causes neuronal dysfunction, with its precise function still under investigation.

Keywords:
Parkinson’s diseaseSNAREneurotransmissionsynapsesynaptic vesiclesynucleinopathies

More Related Videos

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

6.8K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.3K

Related Experiment Videos

Last Updated: Aug 16, 2025

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.7K
Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

6.8K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.3K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pathology

Background:

  • Alpha-synuclein is a neuronal protein concentrated in presynaptic terminals.
  • Its physiological role in neurotransmitter release is unclear, with debated effects on release.
  • Pathological aggregation of alpha-synuclein characterizes synucleinopathies, including Parkinson's disease.

Purpose of the Study:

  • To review the impact of alpha-synuclein on SNARE-complex assembly, neurotransmitter release, and synaptic vesicle homeostasis.
  • To reconcile the conflicting findings on alpha-synuclein's role in neurotransmitter release.
  • To explore the contribution of alpha-synuclein gain-of-function and loss-of-function to synucleinopathy pathogenesis.

Main Methods:

  • Literature review and synthesis of existing research on alpha-synuclein.
  • Analysis of studies investigating alpha-synuclein's interaction with SNARE complexes.
  • Examination of evidence regarding synaptic vesicle dynamics and neurotransmitter release.

Main Results:

  • Alpha-synuclein influences SNARE-complex assembly and synaptic vesicle dynamics.
  • Divergent effects of alpha-synuclein on neurotransmitter release are observed, depending on context.
  • Pathological alpha-synuclein aggregation leads to widespread neuronal dysfunction.

Conclusions:

  • Understanding alpha-synuclein's dual role in health and disease is crucial for synucleinopathy research.
  • Reconciling its physiological and pathological functions may offer therapeutic insights.
  • Both gain-of-function and loss-of-function mechanisms are implicated in synucleinopathies.